Fresenius Medical Care Reports Strong Adjusted Q1 Profit Growth, Completes EUR 1B Share Buyback

summarizeSummary

Fresenius Medical Care AG reported strong adjusted operating income and EPS growth for Q1 2026, alongside a significant increase in cash flow and the successful completion of its EUR 1 billion share buyback program.

check_boxKey Events

• Strong Adjusted Q1 Performance

  Adjusted operating income grew 10% and adjusted EPS increased by 16% at constant currency, indicating solid underlying business health despite reported declines.

• Significant Cash Flow Improvement

  Operating cash flow increased by 39% to EUR 227 million, and free cash flow surged by 94% to EUR 40 million, demonstrating improved liquidity.

• EUR 1 Billion Share Buyback Completed

  The company successfully concluded its EUR 1.0 billion share buyback program on April 30, repurchasing 8.5% of its share capital, which supported EPS growth.

• FME25+ Transformation Progress

  The program delivered EUR 50 million in additional sustainable savings in Q1, though it incurred EUR 166 million in one-time costs, primarily from clinic closures.

auto_awesomeAnalysis

The company's first-quarter results present a mixed picture, with reported revenue and net income declining due to unfavorable currency effects and one-time costs from its FME25+ transformation program. However, adjusted figures, which exclude these special items, demonstrate solid operational performance with a 10% increase in operating income and 16% growth in EPS at constant currency. The significant improvement in operating and free cash flow, coupled with the successful completion of the EUR 1 billion share buyback program, provides a positive signal to investors, especially as the stock trades near its 52-week low. The confirmation of the full-year 2026 outlook suggests management confidence in continued execution of its FME Reignite strategy despite ongoing transformation efforts.